Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board

What are you looking for?

  • Anterior Segment
  • Cataract
  • Cornea and External Disease
  • Diabetic Macular Edema
  • Dry Eye
  • Early Onset Cataracts
  • Exclusives
  • General
  • Geographic Atrophy
  • Glaucoma
  • Industry News
  • Inherited Retinal Disease
  • IOLs
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Oculoplastics
  • Optometry
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Refractive Surgery/Vision Correction
  • Residents & Young Ophthalmologists
  • Retina
  • Retina Care 360
  • Retinopathy of Prematurity
  • Spotlight Series
  • The Interventional Glaucoma Project
  • The Ophthalmic Project
  • Trending Topics
Spotlight - The Future of Cryopreserved Amniotic Membrane in Oculoplastic Surgery
Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board
Home > Retina > Choroidal thickness decreases with age, is significantly thinner in patients with geographic atrophy
  • Retina

Choroidal thickness decreases with age, is significantly thinner in patients with geographic atrophy

Kerri Fitzgerald

Utilizing enhanced depth imaging optical coherence tomography (EDI-OCT), researchers assessed choroidal thickness (CHT) in patients aged 70 years and older and found that CHT decreases with age and is significantly thinner in patients with geographic atrophy (GA). The study was presented at the 2024 ARVO Annual Meeting in Seattle, Washington.

The population-based AugUR study included those with macula scans as generated by the Heidelberg Spectralis OCT device, with subfoveal CHT measured manually with the caliper tool from the Heidelberg Eye Explorer software.

The total patient cohort included 1,831 individuals with CHT measurement and known age-related macular degeneration (AMD) status for at least 1 eye. Median CHT in the 1,389 patients without AMD was 236 μg, with no discernible gender-based variation.

A total of 345 patients had late AMD. CHT decreased with AMD severity and was thinnest in those with GA, indicating a significant association between CHT and GA (odds ratio [OR], 0.992; 95% CI, 0.986-0.997; P=.002). CHT difference between those without AMD and combined GA plus macular neovascularization (MNV) was also significant (OR, 0.992; 95% CI, 0.985-0.999; P=.022). There was no statistically significant association between CHT and MNV only (P=.81) or early AMD stages (P=.94) compared with no AMD.

“Our study aids in establishing normative values for CHT in an elderly population, where data on CHT have been scarce,” the authors noted.

Reference

Luber C, Zimmermann ME, Helbig H, et al. Choroidal thickness in the elderly population and its association with age-related macular degeneration: findings from the population-based AugUR Study. Abstract 1339-B0330. Presented at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting, May 5-9, Seattle, Washington.

Share

Related Content

  • Retina

Aflibercept 8 mg shows comparable IOP safety to 2 mg through 96 weeks

  • Retina

Heidelberg receives FDA clearance for updated SPECTRALIS software

  • Retina

Aflibercept 8 mg demonstrates favorable safety profile in large nAMD cohort

  • Retina

Aflibercept 8 mg shows modest benefits in difficult-to-treat nAMD cases

  • Glaucoma

Review finds low adverse event rates for glaucoma stents

  • Retina

Switching to aflibercept 8 mg extends treatment intervals in suboptimal nARMD responders

Share

Editor's Picks

  • Neurotrophic Keratitis

Topical insulin shows real-world benefit in neurotrophic keratopathy

  • Retina

GLP-1 RAs have protective effects against AMD

  • Retina

Four-month injection intervals appear safe for long-term stable nAMD

Advisory Board

Saad Ahmad, MD

Ahmad A. Aref, MD, MBA

Roomasa Channa, MD

David Chow, MD, FRCS(C)

Sally L. Baxter, MD, MSc

Neel R. Desai, MD

Nadia Haqqie, MD

Simon Fung, MD, FRCOphth

Sumit Garg, MD

Ross Lakhanpal, MD, FACS

Sanjai Jalaj, MD

Anton Kolomeyer, MD, PhD

Shan Lin, MD

Steven R. Sarkisian, Jr., MD

See All
Optometry360 Logo

Ophthalmology 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

2026 Ophthalmology 360 is a trademark of International Healthcare Media, LLC. All rights reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophtalmology360 Icon